vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and QUINSTREET, INC (QNST). Click either name above to swap in a different company.
QUINSTREET, INC is the larger business by last-quarter revenue ($287.8M vs $177.4M, roughly 1.6× Pacira BioSciences, Inc.). QUINSTREET, INC runs the higher net margin — 17.4% vs 1.6%, a 15.8% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 1.9%). Over the past eight quarters, QUINSTREET, INC's revenue compounded faster (53.2% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
QUINSTREET, INCQNSTEarnings & Financial Report
QuinStreet, Inc. is a publicly traded online marketing company based in Foster City, California. The company helps generate web traffic for clients by acquiring popular domain names.
PCRX vs QNST — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $287.8M |
| Net Profit | $2.9M | $50.2M |
| Gross Margin | — | 9.6% |
| Operating Margin | 3.9% | 0.4% |
| Net Margin | 1.6% | 17.4% |
| Revenue YoY | 5.0% | 1.9% |
| Net Profit YoY | — | 3342.5% |
| EPS (diluted) | $0.07 | $0.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $287.8M | ||
| Q3 25 | $179.5M | $285.9M | ||
| Q2 25 | $181.1M | — | ||
| Q1 25 | $168.9M | $269.8M | ||
| Q4 24 | $187.3M | $282.6M | ||
| Q3 24 | $168.6M | $279.2M | ||
| Q2 24 | $178.0M | $198.3M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $50.2M | ||
| Q3 25 | $5.4M | $4.5M | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $4.8M | $4.4M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | $-143.5M | $-1.4M | ||
| Q2 24 | $18.9M | $-2.2M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 9.6% | ||
| Q3 25 | 80.9% | 9.4% | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | 10.3% | ||
| Q4 24 | 78.7% | 9.5% | ||
| Q3 24 | 76.9% | 10.2% | ||
| Q2 24 | 75.1% | 8.8% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 0.4% | ||
| Q3 25 | 3.5% | 1.7% | ||
| Q2 25 | 4.7% | — | ||
| Q1 25 | 1.2% | 1.8% | ||
| Q4 24 | 13.2% | -0.5% | ||
| Q3 24 | -82.8% | -0.4% | ||
| Q2 24 | 15.9% | -0.7% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 17.4% | ||
| Q3 25 | 3.0% | 1.6% | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | 2.8% | 1.6% | ||
| Q4 24 | — | -0.5% | ||
| Q3 24 | -85.1% | -0.5% | ||
| Q2 24 | 10.6% | -1.1% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.87 | ||
| Q3 25 | $0.12 | $0.08 | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.10 | $0.08 | ||
| Q4 24 | $0.38 | $-0.03 | ||
| Q3 24 | $-3.11 | $-0.02 | ||
| Q2 24 | $0.39 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $107.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $294.4M |
| Total Assets | $1.2B | $493.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $107.0M | ||
| Q3 25 | $246.3M | $101.3M | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | $81.8M | ||
| Q4 24 | $484.6M | $57.8M | ||
| Q3 24 | $453.8M | $25.0M | ||
| Q2 24 | $404.2M | $50.5M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $294.4M | ||
| Q3 25 | $727.2M | $246.7M | ||
| Q2 25 | $757.8M | — | ||
| Q1 25 | $798.5M | $235.5M | ||
| Q4 24 | $778.3M | $224.3M | ||
| Q3 24 | $749.6M | $219.8M | ||
| Q2 24 | $879.3M | $216.8M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $493.0M | ||
| Q3 25 | $1.3B | $442.6M | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.6B | $417.2M | ||
| Q4 24 | $1.6B | $409.6M | ||
| Q3 24 | $1.5B | $401.2M | ||
| Q2 24 | $1.6B | $368.5M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $21.6M |
| Free Cash FlowOCF − Capex | — | $20.7M |
| FCF MarginFCF / Revenue | — | 7.2% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | 0.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $106.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $21.6M | ||
| Q3 25 | $60.8M | $19.6M | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $35.5M | $30.1M | ||
| Q4 24 | $33.1M | $38.7M | ||
| Q3 24 | $53.9M | $-13.7M | ||
| Q2 24 | $53.2M | $16.6M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $20.7M | ||
| Q3 25 | $57.0M | $18.4M | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | $29.5M | ||
| Q4 24 | $31.0M | $38.2M | ||
| Q3 24 | $49.8M | $-14.1M | ||
| Q2 24 | $51.6M | $15.4M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 7.2% | ||
| Q3 25 | 31.7% | 6.4% | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | 10.9% | ||
| Q4 24 | 16.6% | 13.5% | ||
| Q3 24 | 29.6% | -5.1% | ||
| Q2 24 | 29.0% | 7.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 2.2% | 0.4% | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | 0.2% | ||
| Q4 24 | 1.1% | 0.2% | ||
| Q3 24 | 2.4% | 0.2% | ||
| Q2 24 | 0.9% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.43× | ||
| Q3 25 | 11.20× | 4.32× | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | 6.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
QNST
| Financial Service | $216.8M | 75% |
| Home Services And Other Revenue | $71.0M | 25% |
